Multiple-marker based algorithms, namely ROMA and OVA1, have also been developed and approved to assess ovarian cancer risk in women with a pelvic mass, showing increased benefit over the traditional CA125 assay. This evidence concerns the gene MUC16 and ovarian cancer.